Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral...

Related Keywords

China ,United States ,American ,Serge Messerlian ,Jennifer Mcintyre ,Obrian Kenney ,Peter Lebowitz ,Caroline Pavis ,Momenta Pharmaceuticals Reports Second Quarter ,Janssen Biotech Inc ,European Hematology Association ,Janssen Pharmaceuticals Inc ,Momenta Pharmaceuticals Inc ,Janssen Research Development ,Janssen Pharmaceutical Companies Of Johnson ,Janssen Pharmaceutical Companies ,American Society Of Hematology ,Development Agreement For Investigational Anti ,National Comprehensive Cancer Network ,Momenta Pharmaceuticals Launches Phase ,None Of The Janssen Pharmaceutical Companies ,Other Administration Reactions ,European Commission ,Drug Administration ,Georgia World Congress Center ,Exchange Commission ,Companies Of Johnson ,European Medicines Agency ,Johnson ,Legend Biotech United States Inc ,American Society ,Annual Meeting ,Global Therapeutic Area Head ,Janssen Research ,Janssen Biotech ,Autoimmune Hemolytic Anemia ,Legend Biotech United States ,Therapy Designation ,Orphan Drug Designation ,Priority Review ,Breakthrough Therapy Designation ,Marketing Authorisation ,National Comprehensive Cancer ,Fcrn Igg ,Fast Track Designation ,Momenta Pharmaceuticals ,Interference With Serological ,Interference With Determination ,Cardiac Failure ,Primary Malignancies ,Lysis Syndrome ,Fetal Toxicity ,Janssen Pharmaceuticals ,Prescribing Information ,Boxed Warnings ,Medication Guide ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Report ,Updated Phase ,Teclistamab Suggest Deep ,Durable Responses ,Heavily Pretreated Multiple Myeloma ,Accessed November ,Serious Conditions ,Presents Updated Data ,First In Class Talquetamab ,Heavily Pretreated Patients ,Multiple Myeloma ,Biotech Announces Global License ,Development Agreement ,Investigational Anti Cancer Agent Daratumumab ,Based Combination Regimen ,Refractory Multiple Myeloma ,Pharmaceuticals Reports Second Quarter ,Pharmaceuticals Launches Phase ,Warm Autoimmune Hemolytic Anemia ,Janssen Pharmaceutical Companies Of Johnson Amp ,